Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research
The study objective is to collect biospecimen samples (e.g., whole blood) from participants diagnosed with active lung cancer to investigate the immune response to develop treatments and therapies.
Checked against the public recordLast updated Nov 22, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Sanguine Biosciences
- Interventions being studied
- Diagnostic Test: Specimen sample
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Participants willing and able to provide written informed consent * Participants are willing and able to provide appropriate photo identification * Participant's age 18 - 100 years old * Participants diagnosed with active non-small cell lung cancer (Adenocarcinoma or Squamous Cell only. All stages are acceptable.) * Participants must have associated tissue biomarker data (EFGR and MET mutations) in their medical records Exclusion Criteria: * Participants who are pregnant or nursing * Participants with a known history of HIV, hepatitis, or other infectious diseases * Participants who have taken an investigational product in the last 30 days * Participants who have experienced excess blood loss, including blood donation defined as 250 mL in the last month or 500 mL in the previous two months * Participants currently enrolled in a clinical trial * Participants currently in remission
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Sanguine BiosciencesWaltham, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 22, 2023. Always confirm current availability with the study team.